Michael Alan Steinman

Michael Alan Steinman

Auto-generated profile, based on publicly available information

Michael Alan Steinman

Division of Geriatrics University of California, San Francisco San Francisco California USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2006 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
MSMichael A. Steinman
Michael A. Steinman
CLC. Seth Landefeld
C. Seth Landefeld
GRGary E. Rosenthal
Gary E. Rosenthal
DBDaniel Berthenthal
Daniel Berthenthal
SSSaunak Sen
Saunak Sen
PKPeter J. Kaboli
Peter J. Kaboli

15 August 2006 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
MSMichael A. Steinman
Michael A. Steinman
LBLisa A. Bero
Lisa A. Bero
MCMary-Margaret Chren
Mary-Margaret Chren
CLC. Seth Landefeld
C. Seth Landefeld
Background: Internal documents from the pharmaceutical industry provide a unique window for understanding the structure and methods of pharmaceutical promotion. Such documents have become available through litigation concerning the promotion of gabapentin (Neurontin, Pfizer, Inc., New York, New York) for off-label uses. Purpose: To describe how gabapentin was promoted, focusing on the use of medical education, research, and publication. Data Sources: Court documents available to the public from United States ex. rel David Franklin vs. Pfizer, Inc., and Parke-Davis, Division of Warner-Lambert Company, mostly from 1994–1998. Data Extraction: All documents were reviewed by 1 author, with selected review by coauthors. Marketing strategies and tactics were identified by using an iterative process of review, discussion, and re-review of selected documents. Data Synthesis: The promotion of gabapentin was a comprehensive and multifaceted process. Advisory boards, consultants meetings, and accredited continuing medical education events organized by third-party vendors were used to deliver promotional messages. These tactics were augmented by the recruitment of local champions and engagement of thought leaders, who could be used to communicate favorable messages about gabapentin to their physician colleagues. Research and scholarship were also used for marketing by encouraging “key customers” to participate in research, using a large study to advance promotional themes and build market share, paying medical communication companies to develop and publish articles about gabapentin for the medical literature, and planning to suppress unfavorable study results. Limitations: Most available documents were submitted by the plaintiff and may not represent a complete picture of marketing practices. Conclusion: Activities traditionally considered independent of promotional intent, including continuing medical education and research, were extensively used to promote gabapentin. New strategies are needed to ensure a clear separation between scientific and commercial activity.

13 October 2010 in JAMA
Verified
Journal Article
Closed access
PDF file
MSMichael A. Steinman
Michael A. Steinman
JHJoseph T. Hanlon
Joseph T. Hanlon
Multiple medication use is common in older adults and may ameliorate symptoms, improve and extend quality of life, and occasionally cure disease. Unfortunately, multiple medication use is also a major risk factor for prescribing and adherence problems, adverse drug events, and other adverse health outcomes. Using the case of an older patient taking multiple medications, this article summarizes the evidence-based literature about improving medication use and withdrawing specific drugs and drug classes. It also describes a systematic approach for how health professionals can assess and improve medication regimens to benefit patients and their caregivers and families.

1 June 2020 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
MSMichael A. Steinman
Michael A. Steinman
LPLaura Perry
Laura Perry
CPCarla M. Perissinotto
Carla M. Perissinotto
This Viewpoint stresses the importance of recognizing and directly addressing the challenges created by COVID-19 era physical distancing in the care of older ad

28 July 2011 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
MSMichael A. Steinman
Michael A. Steinman
SHSteven M. Handler
Steven M. Handler
JGJerry H. Gurwitz
Jerry H. Gurwitz
GSGordon D. Schiff
Gordon D. Schiff
KCKenneth E. Covinsky
Kenneth E. Covinsky

4 October 2012 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
MSMichael A. Steinman
Michael A. Steinman
SLSei J. Lee
Sei J. Lee
WBW. John Boscardin
W. John Boscardin
YMYinghui Miao
Yinghui Miao
KFKathy Z. Fung
Kathy Z. Fung
JSJanice B. Schwartz
Janice B. Schwartz